Drug intelligence / Profile preview

ketorolac + fluorometholone

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Ophthalmic

Overview

This is a combination of two separate ophthalmic medications: ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), and fluorometholone, a corticosteroid. These medications are not typically formulated together as a single product but have been studied comparatively for treating ocular inflammation after cataract surgery and for seasonal allergic conjunctivitis. Ketorolac works by blocking prostaglandin biosynthesis, while fluorometholone is a glucocorticoid that provides anti-inflammatory effects.

Targets

GR (Glucocorticoid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on ketorolac + fluorometholone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketorolac + fluorometholone.

Explore the full profile